Rakuten Medical Raises $100 Million in Oversubscribed Series F to Accelerate Development Toward U.S. Regulatory Approval
By SquaredTown on January 7, 2026
Proceeds to drive global Phase 3 trial for ASP-1929, targeting BLA submission to the U.S. FDA in 2028 Financing led by international life science fund TaiAx, with participation from the largest number of institutional investors in Rakuten Medical's history, alongside strategic partners...